Morgan Stanley Reiterates Equal-Weight on Ascendis Pharma, Maintains $109 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit has reiterated an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a $109 price target.
July 31, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Ascendis Pharma and maintained a $109 price target.
The news is directly about Ascendis Pharma and is likely to influence investor sentiment. However, as the rating and price target have been maintained, the immediate impact on the stock price may be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100